Susquehanna International Group’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding AVTX
DTC
CP
TCM
AAA
FCM
ACA
Susquehanna International Group's AVTX Position: Q2 2026 in Review
Susquehanna International Group opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 27,227 shares worth $503K. The stake represents ﹤0.01% of the portfolio and ranks #9914 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in AVTX as recently as Q4 2025.
Susquehanna International Group first reported a position in AVTX in Q1 2019 and has held it in 16 quarters since. The position peaked at $3.83M in Q4 2025. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.
- Susquehanna International Group held 27,227 shares of Avalo Therapeutics worth $503K as of Q2 2026.
- Avalo Therapeutics was a new Susquehanna International Group position in Q2 2026.
- Avalo Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #9914 holding.
- Susquehanna International Group first reported a position in Avalo Therapeutics in Q1 2019 and has held it in 16 quarters since.
- Susquehanna International Group's Avalo Therapeutics position peaked at $3.83M in Q4 2025.
- 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.